The stock price of Moderna decreased by 2.3% on Friday because investors became uncertain about the CDC advisory panel’s decision to support the expanded use of the newly approved RSV vaccine from the company.
The mRNA-based vaccine mRESVIA gained U.S. regulatory approval for adults between 18 and 59 years old who have health conditions. The vaccine already has approval for use in people above 60 years old. The rollout for younger adults depends on the Advisory Committee on Immunization Practices (ACIP) from the CDC giving their endorsement.
The support for the vaccine now faces uncertainty because Health Secretary Robert F. Kennedy Jr. removed all 17 ACIP members this week and selected new members who have shown skepticism about vaccines. The new panel members might show less acceptance of mRNA technology which could reduce the adoption rate of Moderna’s vaccine.
Morningstar analyst Karen Andersen stated that the new ACIP members fear mRNA technology in a negative way.
The CDC recommends RSV vaccination for adults aged 75 and older and specific high-risk individuals between 60 to 74 years old. Moderna seeks the ACIP to provide recommendations for expanded vaccine coverage and revaccination in the future.
The company’s vaccine revenue potential remains uncertain until the necessary regulatory approvals are received.
